MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2023010302

Медицинская библиотека · Blood advances · 2023

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.

Scordo Michael, Flynn Jessica R, Gonen Mithat, Devlin Sean M, Parascondola Allison, Tomas Ana Alarcon, Shouval Roni, Brower Jamie, Porter David L, Schuster Stephen J, Bachanova Veronika, Maakaron Joseph, Maziarz Richard T, Chen Andy I, Nastoupil Loretta J, McGuirk Joseph P, Oluwole Olalekan O, Ip Andrew, Leslie Lori A, Bishop Michael R, Riedell Peter A, Perales Miguel-Angel

Многоцентровое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Fludarabine is one of the most common agents given for lymphodepletion before CD19 chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data from a multicenter consortium, we estimated fludarabine exposure (area under the curve [AUC]) using a population pharmacokinetic (PK) model in 199 adult patients with aggressive B-cell non-Hodgkin lymphomas who received commercial axicabtagene ciloleucel (Axi-cel). We evaluated the association of estimated fludarabine AUC with key outcomes, aiming to find an AUC that optimized efficacy and tolerability. We identified low (<18 mg × hour/L [mgh/L]), optimal (18-20 mgh/L), and high (>20 mgh/L) AUC groups for analyses; the 6-month cumulative incidences of relapse/progression of disease (relapse/POD) by AUC groups were 54% (45%-62%), 28% (15%-44%), and 30% (14%-47%), respectively; and the 1-year progression-free survival (PFS) rates were 39% (31%-48%), 66% (52%-84%), and 46% (30%-70%) and the overall survival (OS) rates were 58% (50%-67%), 77% (64%-92%), and 66% (50%-87%), respectively. In multivariable analyses compared with low AUC, an optimal AUC was associated with the highest PFS (hazard ratio [HR], 0.52; 0.3-0.91; P = .02) and lowest risk of relapse/POD (HR, 0.46; 0.25-0.84; P = .01) without an increased risk of any-grade cytokine release syndrome (HR, 1.1; 0.7-1.6; P = .8) or and immune effector cell-associated neurotoxicity syndrome (ICANS) (HR, 1.36; 0.83-2.3; P = .2). A high AUC was associated with the greatest risk of any-grade ICANS (HR, 1.9; 1.1-3.2; P = .02). Although the main cause of death in all groups was relapse/POD, nonrelapse-related deaths, including 3 deaths from ICANS, were more frequent in the high AUC group. These findings suggest that PK-directed fludarabine dosing to achieve an optimal AUC may result in improved outcomes for patients receiving axi-cel.

Для цитирования: Scordo Michael, Flynn Jessica R, Gonen Mithat, Devlin Sean M, Parascondola Allison, Tomas Ana Alarcon, Shouval Roni, Brower Jamie, Porter David L, Schuster Stephen J, Bachanova Veronika, Maakaron Joseph, Maziarz Richard T, Chen Andy I, Nastoupil Loretta J, McGuirk Joseph P, Oluwole Olalekan O, Ip Andrew, Leslie Lori A, Bishop Michael R, Riedell Peter A, Perales Miguel-Angel. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.. Blood advances. 2023. DOI: 10.1182/bloodadvances.2023010302.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.